Published on 14 December 2016
An empirical study of market-based purchasing policies for generic pharmaceuticals in Sweden
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.050
4.093 views
Published on 14 December 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.050
4.093 views
Published on 12 December 2016
Author(s): Emmanuelle Charton, PhD
biotherapeutic products, complexity of biologicals, monographs, pharmacopoeia, public standards
DOI: 10.5639/gabij.2016.0504.045
20.416 views
Published on 12 December 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.051
5.008 views
Published on 31 October 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.049
4.116 views
Published on 31 October 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.048
6.953 views
Published on 31 October 2016
2.526 views
Published on 26 October 2016
Author(s): Beat Flühmann, PhD, Jon SB de Vlieger, PhD, Professor Gerrit Borchard, PharmD, PhD, Professor Stefan Mühlebach, PhD, Sesha Neervannan, PhD, Vinod P Shah, PhD
complex drug products, EMA, generics, harmonization, non-biological complex drug (NBCD), therapeutic equivalence, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2016.0503.026
7.139 views
Published on 26 October 2016
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2016.0503.025
3.153 views
Published on 26 October 2016
Author(s): Brendan T Griffin, PhD, Frank Hallinan, PhD, J Michael Morris, PhD, Joan O’Callaghan, BSc Pharm, Margaret Bermingham, PhD, Sean Barry, PhD, Una Moore, PhD
biological medicines, biosimilar, Health Products Regulatory Authority, regulatory science, Regulatory Science Ireland
DOI: 10.5639/gabij.2016.0504.043
9.397 views
Published on 26 October 2016
Author(s): Adjunct Professor Pekka Kurki, MD, PhD
automatic substitution, FDA guidelines, global reference product, information, interchangeability, regulatory harmonization
DOI: 10.5639/gabij.2018.0702.011
7.845 views
Published on 26 October 2016
Author(s): Amit Garg, MD, Shyam Akku, MD, Suhas Khandarkar, MPharm
anticancer drugs, cost-minimization, generics, pharmacoeconomics
DOI: 10.5639/gabij.2016.0504.042
15.877 views
Published on 26 October 2016
Author(s): Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
ASBM, biologicals, biosimilars, labelling, naming, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2016.0504.040
9.114 views